Julian Lieb, M.D
Prostaglandins are tiny molecules regulating the chemistry of every cell, including those subserving mood, and those subserving immune function. When brain cells produce excessive concentrations of prostaglandins, they depress mood and immunity. In 1973, David Horrobin showed that antidepressants inhibit prostaglandins, and in 1977 that prostaglandins regulate nucleic acids (DNA and RNA). Others subsequently showed that prostaglandins regulate the synthesis, inhibition, and expression of genes, and the growth and replication of cells, with cancer the accelerated replication of abnormal cells. Excessive synthesis of prostaglandins induces cancer, with genes determining the variations. Twenty years ago, prostaglandins owned cancer, but evidence often goes only so far, before falling prey to monopolistic medical cartels.
More than fifty studies have shown that antidepressants kill cancer cells, inhibit their replication, convert multidrug resistant cells to sensitive,
protect nonmalignant cells from damage by radiation and chemotherapy, and target the mitochondria of cancer cells while sparing those of healthy ones. Antidepressants have efficacy in many cancers that are often treatment resistant, such as gliomas, cancers of the lung, kidney, liver, and uterus,
inflammatory breast cancer, and multiple myelomas. Antidepressants are capable of arresting cancer in advanced stages, and even reversing it. That
antidepressants are effective for a multitude of malignancies, decries the myth that cancer is a hundred diseases, when it is one disease with a
hundred variations. Depression predisposes to cancer, and accelerates and increases its mortality. Other inhibitors of prostaglandins, such as
non-steroidal, anti-inflammatory drugs and COX-11 inhibitors, also have potential value in cancer therapeutics.
All of the ingredients are in place for a revolution in cancer prevention and treatment. Enter Medline or Pubmed, enter “antidepressants” and
“cancer,” and anyone may see for themselves.
Julian Lieb, M.D